Markus J. Cappel Sells 5,069 Shares of ChemoCentryx Inc (CCXI) Stock
ChemoCentryx Inc (NASDAQ:CCXI) Treasurer Markus J. Cappel sold 5,069 shares of the business’s stock in a transaction dated Monday, January 7th. The stock was sold at an average price of $12.07, for a total value of $61,182.83. Following the transaction, the treasurer now owns 40,510 shares in the company, valued at approximately $488,955.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Shares of ChemoCentryx stock opened at $12.38 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.87 and a quick ratio of 2.87. The stock has a market capitalization of $600.24 million, a P/E ratio of 34.39 and a beta of 1.38. ChemoCentryx Inc has a fifty-two week low of $8.01 and a fifty-two week high of $15.08.
ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.03. The firm had revenue of $8.98 million during the quarter, compared to analyst estimates of $11.55 million. ChemoCentryx had a return on equity of 32.16% and a net margin of 13.88%. Equities research analysts anticipate that ChemoCentryx Inc will post -0.83 earnings per share for the current fiscal year.
CCXI has been the topic of a number of recent research reports. ValuEngine upgraded ChemoCentryx from a “hold” rating to a “buy” rating in a research note on Wednesday, September 19th. BidaskClub upgraded ChemoCentryx from a “hold” rating to a “buy” rating in a research note on Thursday, October 18th. Canaccord Genuity lifted their target price on ChemoCentryx from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, November 12th. B. Riley initiated coverage on ChemoCentryx in a research report on Tuesday. They set a “neutral” rating and a $12.50 target price on the stock. Finally, Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Wednesday. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and three have assigned a strong buy rating to the stock. ChemoCentryx currently has a consensus rating of “Buy” and a consensus target price of $16.42.
ILLEGAL ACTIVITY NOTICE: “Markus J. Cappel Sells 5,069 Shares of ChemoCentryx Inc (CCXI) Stock” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2019/01/11/markus-j-cappel-sells-5069-shares-of-chemocentryx-inc-ccxi-stock.html.
ChemoCentryx Company Profile
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).
See Also: What is a stock split?
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.